| Endometrial Cancer |
1 |
1 |
| Cancer |
0 |
0.77 |
| Metastasis |
0 |
0.58 |
| Hereditary Nonpolyposis Colorectal Cancer (HNPCC) |
0 |
0.56 |
| Cancer Staging |
0 |
0.55 |
| Colorectal Cancer |
0 |
0.49 |
| Surgery |
0 |
0.99 |
| Toxicology |
0 |
0.39 |
| Obesity |
0 |
0.36 |
| Hormonal Therapy |
0 |
0.35 |
| Thromboembolism |
0 |
0.29 |
| Fertility |
0 |
0.27 |
| Care and Maintenance of Vision |
0 |
0.26 |
| Receptors |
0 |
0.15 |
| Contraception |
0 |
0.13 |
| Estrogen |
0 |
0.12 |
| Hysterectomy |
0 |
0.12 |
| Intrauterine Device |
0 |
0.12 |
| Adverse Effects |
0 |
0.08 |
| Lymph Node |
0 |
0.08 |
| Tumor |
0 |
0.08 |
| Patient Safety |
0 |
0.07 |
| Coronary Artery Disease (CAD) |
0 |
0.06 |
| Infertility Female |
0 |
0.06 |
| Adherence |
0 |
0.04 |
| Adjuvant Therapy |
0 |
0.04 |
| Artery |
0 |
0.04 |
| Biopsy |
0 |
0.04 |
| Bladder |
0 |
0.04 |
| Body Mass Index |
0 |
0.04 |
| Fundus |
0 |
0.04 |
| Gonadotropin-Releasing Hormone (GnRH) Agonists |
0 |
0.04 |
| Infertility |
0 |
0.04 |
| Oophorectomy |
0 |
0.04 |
| Pelvis |
0 |
0.04 |
| Polycystic Ovary Syndrome |
0 |
0.04 |
| Progestin |
0 |
0.04 |
| Salpingectomy |
0 |
0.04 |
| Tissue |
0 |
0.04 |
| Uterus |
0 |
0.04 |
| Venous Thromboembolism (VTE) |
0 |
0.04 |
| Hypertension |
0 |
0.03 |